Back to Search
Start Over
Aberrant Expression of Prohibitin Is Related to Prognosis of Nasal Extranodal Natural Killer/T Cell Lymphoma, Nasal Type
- Source :
- Oncology Research and Treatment. 43:491-497
- Publication Year :
- 2020
- Publisher :
- S. Karger AG, 2020.
-
Abstract
- Introduction: Nasal extranodal natural killer (NK)/T cell lymphoma, nasal type (ENKTCL) is a high-grade Epstein-Barr virus (EBV)-associated malignancy with poor outcomes. There are few biomarkers for the accurate diagnosis and prognostic prediction of the disease. The aim of this study was to investigate the clinicopathological significance of prohibitin (PHB) expression in nasal ENKTCL. Methods: The expression level of PHB was detected via immunohistochemical staining in 49 nasal ENKTCL tissues and age- and sex-matched controls of 30 nasal mucosa-reactive lymphoid hyperplasia (NRLH) tissues. The correlations between the PHB expression and clinicopathological features of patients with nasal ENKTCL were evaluated. Results: The results indicated a significantly decreased expression of PHB in nasal ENKTCL tissues compared with in NRLH tissues. Low-level PHB expression was significantly associated with younger age and fever (p = 0.008 and 0.018, respectively). The Kaplan-Meier analysis showed that the cytoplasm expression level of PHB in nasal ENKTCL was inversely related to overall survival (p = 0.046). Conclusions: PHB may be a potential diagnostic marker and prognostic predictor of nasal ENKTCL.
- Subjects :
- Cancer Research
Pathology
medicine.medical_specialty
Fever
Nose Neoplasms
Kaplan-Meier Estimate
macromolecular substances
Malignancy
Lymphoid hyperplasia
Virus
Prohibitins
otorhinolaryngologic diseases
Humans
Medicine
T-cell lymphoma
Prohibitin
Lactate Dehydrogenases
business.industry
Age Factors
technology, industry, and agriculture
Hematology
Middle Aged
Prognosis
Natural killer T cell
medicine.disease
Immunohistochemistry
Lymphoma
Lymphoma, Extranodal NK-T-Cell
Repressor Proteins
Survival Rate
Oncology
lipids (amino acids, peptides, and proteins)
medicine.symptom
business
Biomarkers
Subjects
Details
- ISSN :
- 22965262 and 22965270
- Volume :
- 43
- Database :
- OpenAIRE
- Journal :
- Oncology Research and Treatment
- Accession number :
- edsair.doi.dedup.....3264ade37f3b2569e68cd6ead64e8d3a